Related Experiment Video
Updated: Sep 4, 2026

Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa
Published on: June 30, 2016
The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic Development
Manica Balasegaram1, Laura J V Piddock1
1Global Antibiotic Research and Development Partnership (GARDP), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland.
Abstract:
The Global Antibiotic Research and Development Partnership (GARDP) brings together public and private partners to accelerate the development and global availability of new antibiotics to treat the most challenging drug-resistant bacterial infections. Established in 2016, GARDP's recently launched strategy sets out its ambitious aim to deliver five new treatments by 2025, focusing on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children.
Related Concept Videos
Antibiotic Selection
Development of Antibiotic Resistance
Production of Antibiotics
Microbiota Modulation by Antibiotics
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance

